PMS2 and posterior cortical atrophy: Furthermore, PCA screening guidelines advocate for starting screening at a younger age (age 40 years) compared to the general population for males who carry mutations in BRCA2, BRCA1, ATM, CHEK2, PALB2, HOXB13, MLH1, MSH2, MSH6, PMS2, EPCAM, and TP53 due to higher risk for PCA and aggressive disease for some of these genes [3].